Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avalo Therapeutics Inc

6.59
-0.4900-6.92%
Post-market: 6.33-0.2566-3.89%17:18 EDT
Volume:41.24K
Turnover:275.80K
Market Cap:70.33M
PE:-0.32
High:7.00
Open:6.90
Low:6.40
Close:7.08
Loading ...

Company Profile

Company Name:
Avalo Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
23
Office Location:
540 Gaither Road,Suite 400,Rockville,Maryland,United States
Zip Code:
20850
Fax:
- -
Introduction:
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Directors

Name
Position
Garry Neil
Chairman of the Board, President, Chief Executive Officer
Gilla Kaplan
Director
June Almenoff
Director
Magnus Persson
Director
Mitchell Chan
Director

Shareholders

Name
Position
Garry Neil
Chairman of the Board, President, Chief Executive Officer
Christopher Sullivan
Chief Financial Officer